Global News

Shire, Santaris extend collaboration to discover and develop LNA-drugs

Friday, August 23, 2013 12:29 PM

Santaris Pharma, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, has announced that its long-term partner, Shire, has extended the existing partnership in the rare genetic disease space.  

More... »

Takeda expands to Peru

Friday, August 23, 2013 12:22 PM

Zurich-based Takeda Pharmaceuticals International has further expanded its presence in Latin America with the launch of a wholly-owned subsidiary in Peru. Takeda Peru S.R.L. will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products in Peru.

More... »

Vical restructures, 39% staff reduction

Friday, August 23, 2013 12:15 PM

Vical, which researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases, has announced a restructuring to conserve capital, including a staff reduction of 47 employees, approximately 39% of the company's total workforce. Following the restructuring, the company will have approximately 74 employees. In addition, the company is focusing its resources on its infectious disease vaccine programs and terminating activities related to Allovectin, the company's investigational cancer immunotherapy which recently failed to meet its phase III efficacy endpoints.

More... »

Decision Resources suggests breast cancer market to reach $15B by 2022

Friday, August 23, 2013 11:39 AM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium-priced agents will fuel 5% annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan.

More... »

ACRES launches global clinical research network technology platform

Friday, August 23, 2013 11:32 AM

The Alliance for Clinical Research Excellence and Safety (ACRES), analytics company ViS Research and HealthCarePoint (HCP), will officially begin registering clinical research sites worldwide. This is the first step in the development of the ACRES Global Network of high-performing sites, part of an open, global system for clinical research. This network will ultimately include thousands of sites worldwide connected through a shared technology platform.

More... »

Patricia Monteforte named president of Trio Clinical Resourcing

Wednesday, August 21, 2013 04:40 PM

Aptiv Solutions, a global biopharmaceutical and medical device development services company, has appointed Patricia Monteforte president of Trio Clinical Resourcing, an Aptiv Solutions subsidiary focused on clinical and regulatory staffing. Monteforte will leverage more than 25 years in the pharmaceutical industry and success leading CROs to assemble teams of clinical and regulatory professionals to deliver flexible resourcing solutions to meet the current and future challenges in the pharmaceutical and medical device industry.

More... »

Navidea awarded NIH SBIR grant

Wednesday, August 21, 2013 04:19 PM

Navidea Biopharmaceuticals, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute On Aging (NIA) of the NIH in connection with the company's phase III clinical program for its NAV4694 beta-amyloid imaging agent as an aid in the differential diagnosis of Alzheimer's disease.

More... »

Litera acquires AxxiTRIALS Clinical Trials Portal

Wednesday, August 21, 2013 10:30 AM

Litera has acquired AxxiTRIALS, a Clinical Trials Portal solution providing life science companies and CROs with a platform designed to speed site startup, patient recruitment and end-to-end clinical trial operations.

More... »

Adimab, Celgene collaborate for antibody discovery

Wednesday, August 21, 2013 10:22 AM

Adimab, a technology company focuses on the discovery of fully human antibodies, has announced a multi-target discovery collaboration with Celgene of Summit, NJ. Adimab will use its proprietary platform to generate therapeutic antibodies against multiple targets. Celgene will have the right to develop and commercialize all therapeutic antibodies resulting from the collaboration.

More... »

PSI expands to India, names Radhika Bobba regional director

Wednesday, August 21, 2013 10:16 AM

Privately-held, Switzerland-based CRO PSI  has expanded to India. PSI’s decided to conduct clinical trials in India based on client requests. The PSI Indian base is a hub for continuous expansion into the entire Asia-Pacific region.

More... »